U.S. Residents

The Scientific Intake website is not intended for a U.S. audience. The website describes our product, Sensor Monitored Alimentary Restriction Therapy (SmartByte™). The product has not been cleared for marketing by the Food and Drug Administration and is not available for sale in the U.S.

SmartByte™ is limited by U.S. law to investigational use only. It has been designated Non Significant Risk by the FDA.

Outside the U.S., Scientific Intake's SmartByte™ is designated a Class I medical device and has been granted the CE Mark (Europe), and has been approved by Health Canada, Anvisa ( Brazil) and TGA (Australia).

I Understand

Real Results

comp_01

SmartByte™ is Placed in the Upper Palate Only During Meals

SmartByte™ has been evaluated in a number of prospective, randomized controlled studies conducted under the highest scientific standards. Some important findings  from research on SmartByte™ conducted at The Pennington Biomedical Research Center(LSU)  and at Monash University, Melbourne Australia and published in the peer reviewed journal Obesity include:

Pilot Study

  • SmartByte™ users reduced their daily food intake by 23%.
  • SmartByte™ subjects consumed 533 fewer calories over the course of a day.
  • SmartByte™ users ate less but did not get hungry sooner than non-SmartByte™ users.

After Four Months

  • Excess body weight loss (i.e., the difference between ideal weight and actual weight) averaged 38.1% among subjects who used the device as directed. Study participants that used the device as directed averaged – 6% total body weight loss in four months.
  • BMI decreased from an average of 31.5 to 29.5
  • Cognitive Restraint when eating increased 47%
  • Dis-inhibition when eating decreased  68%
  • Hunger went from a baseline score of 9.75 to 5.45 among compliant SmartByte™ users.

See Science & Research for additional information.

 

Read what McLeans magazine says about SmartByte™bite.

Read what McLeans magazine says about SmartByte™.

© 2017 Scientific Intake Limited Co.